CELLinCELLS

CELLinCELLS is a South Korea-based clinical-stage regenerative medicine biotechnology company developing organoid-based therapeutics. The company is built around its proprietary 3D Tissue Reforming Technology Platform (TRTP), which uses stem-cell self-organization and principles of human embryology to manufacture tissue-like organoid modules without synthetic scaffolds. Its lead asset, TRTP-101, is a skin regenerative therapy for atrophic scars and has advanced from Phase 1 into Phase 2 preparation/early Phase 2 activity in Korea. Beyond dermatology, the company is expanding organoid regenerative programs in cartilage, musculoskeletal, and other degenerative conditions. CELLinCELLS also markets its platform for licensing, co-development, and broader applications in organoid manufacturing, AI-based organoid assessment, and longevity-oriented regenerative medicine.